Vascular access management after percutaneous transluminal angioplasty using a calcium alginate sheet: a randomized controlled trial.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 30 11 2017
pubmed: 31 5 2018
medline: 26 3 2020
entrez: 31 5 2018
Statut: ppublish

Résumé

Management of vascular access (VA) is essential in hemodialysis (HD) patients. However, VA often fails and percutaneous transluminal angioplasty (PTA) is required. Conventional hemostasis at the puncture site is associated with complications. This study aimed to analyze the efficacy and safety of a hemostatic wound dressing made of calcium alginate at the puncture site of VA after PTA and evaluate other factors affecting hemostasis. After PTA for VA, 200 HD patients were randomized to a calcium alginate sheet (CA) group (n = 100) or a no drug-eluting sheet (control) group (n = 100). We recorded time to hemostasis at the puncture site every 5 min, noting any complications. In the CA group, rates of hemostatic achievement at 5, 10, 15 and >15 min were 57, 25, 8 and 10%, respectively. In the control group, the rates were 39, 28, 14 and 19%, respectively. Rates of hemostatic achievement at 5 min were significantly higher in the CA group (P = 0.01). In logistic regression analysis, factors affecting hemostasis within 5 min were use of the CA sheet [odds ratio (OR) 2.33; 95% confidence interval (CI) 1.26-4.37], platelet count ≤100 000/μL (OR 0.19; 95% CI 0.04-0.69), number of antithrombotic tablets used per day ≥1 tablet (OR 0.50; 95% CI 0.26-0.94) and upper arm VA (OR 0.16; 95% CI 0.03-0.55). A CA sheet can safely reduce time to hemostasis at the puncture site after PTA, and should be considered for treating patients with a bleeding tendency.

Sections du résumé

BACKGROUND
Management of vascular access (VA) is essential in hemodialysis (HD) patients. However, VA often fails and percutaneous transluminal angioplasty (PTA) is required. Conventional hemostasis at the puncture site is associated with complications. This study aimed to analyze the efficacy and safety of a hemostatic wound dressing made of calcium alginate at the puncture site of VA after PTA and evaluate other factors affecting hemostasis.
METHODS
After PTA for VA, 200 HD patients were randomized to a calcium alginate sheet (CA) group (n = 100) or a no drug-eluting sheet (control) group (n = 100). We recorded time to hemostasis at the puncture site every 5 min, noting any complications.
RESULTS
In the CA group, rates of hemostatic achievement at 5, 10, 15 and >15 min were 57, 25, 8 and 10%, respectively. In the control group, the rates were 39, 28, 14 and 19%, respectively. Rates of hemostatic achievement at 5 min were significantly higher in the CA group (P = 0.01). In logistic regression analysis, factors affecting hemostasis within 5 min were use of the CA sheet [odds ratio (OR) 2.33; 95% confidence interval (CI) 1.26-4.37], platelet count ≤100 000/μL (OR 0.19; 95% CI 0.04-0.69), number of antithrombotic tablets used per day ≥1 tablet (OR 0.50; 95% CI 0.26-0.94) and upper arm VA (OR 0.16; 95% CI 0.03-0.55).
CONCLUSIONS
A CA sheet can safely reduce time to hemostasis at the puncture site after PTA, and should be considered for treating patients with a bleeding tendency.

Identifiants

pubmed: 29846686
pii: 5017398
doi: 10.1093/ndt/gfy143
doi:

Substances chimiques

Alginates 0

Types de publication

Clinical Trial Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1592-1596

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Makoto Matsubara (M)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Masataka Banshodani (M)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Akira Takahashi (A)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Yusuke Kawai (Y)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Tomoki Saiki (T)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Masahiro Yamashita (M)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Nobuaki Shiraki (N)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Sadanori Shintaku (S)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Misaki Moriishi (M)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.

Takao Masaki (T)

Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.

Hideki Kawanishi (H)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.
Department of Transplant Surgery, Hiroshima University Hospital, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH